Clinical Edge Journal Scan

Acute exacerbation affects prognosis in RA-associated interstitial lung disease


 

Key clinical point: Almost one-third of patients with rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) experience acute exacerbation (AE), which significantly affects overall survival.

Major finding: Overall, AE was experienced by 28.1% of patients with RA-ILD, with the 5-year cumulative incidence being 29.4%. The occurrence of AE was significantly associated with a higher risk for mortality (adjusted hazard ratio 2.423; P < .001).

Study details: The findings come from a retrospective analysis involving 310 patients with RA-ILD.

Disclosures: This study was supported by a grant from the Basic Science Research Program through the National Research Foundation of Korea, funded by the Ministry of Science and Technology. All the authors declared no conflicts of interest.

Source: Kwon BS et al. Chest. 2022 (Jan 11). Doi: 10.1016/j.chest.2022.01.007

Recommended Reading

Upadacitinib inhibits structural joint damage progression in RA
MDedge Rheumatology
Upadacitinib inhibits structural joint damage progression in RA
MDedge Rheumatology
Clinical Edge Journal Scan Commentary: RA February 2022
MDedge Rheumatology
Lilly calls it quits on baricitinib’s development for lupus
MDedge Rheumatology
Boxed warning for JAK inhibitors belies their durability in real-world registry studies
MDedge Rheumatology
Dietary recommendations for inflammatory rheumatic diseases
MDedge Rheumatology
Patients are interrupting DMARD use well into the COVID-19 pandemic
MDedge Rheumatology
Treat-to-target in RA: Questions remain about adoption, measurement
MDedge Rheumatology
Rheumatoid arthritis: Higher risk for MACE and cancer with tofacitinib vs. TNF inhibitors
MDedge Rheumatology
More evidence supporting ultra-low retreatment dose of rituximab in RA
MDedge Rheumatology